Core Viewpoint - Shunhao Co., Ltd. plans to issue H shares and list on the Hong Kong Stock Exchange despite declining performance and ongoing legal issues, raising questions about the necessity and feasibility of the IPO [1][10]. Financial Performance - Shunhao's revenue and net profit have been on a downward trend since 2018, with revenue failing to exceed the 2018 peak of 20.55 billion yuan, and net profit showing significant losses in several years [4][5]. - In the first half of 2025, the company reported revenue of 620 million yuan and a net profit of 29 million yuan, representing year-on-year declines of 12.19% and 6.24% respectively [6]. Employee Reduction - The company has reduced its workforce by nearly 50% over the past seven years, from 2,121 employees in 2017 to 1,116 in 2024, indicating ongoing operational challenges [7][9]. Acquisition Issues - Shunhao has faced significant losses due to problematic acquisitions, such as the 2013 purchase of Zhejiang Demei, which led to a loss of 51 million yuan in 2014 due to management misconduct [5][6]. Legal and Compliance Challenges - The company is currently under investigation for alleged unit bribery, which poses a significant obstacle to its IPO plans, as compliance with regulatory standards is critical for approval from both the China Securities Regulatory Commission and the Hong Kong Stock Exchange [11][12][13].

Group 1 - The core viewpoint of the news is that Shunhao Co., Ltd. plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and competitiveness [2] - The company is actively discussing the issuance and listing with relevant intermediaries, and specific details are yet to be finalized [2] - Shunhao Co., Ltd. has appointed Hong Kong Lixin as the auditing firm for this issuance and listing [2] Group 2 - Shunhao Co., Ltd. was established in 2004 and focuses on eco-friendly packaging materials, new tobacco products, and industrial hemp, with a clear business structure [3] - The company employs nearly 1,200 people and has around 30 subsidiaries located in various regions including the US, Cambodia, and several provinces in China [3] - As of August 18, the company's market capitalization is approximately 9.042 billion RMB [3]

Core Viewpoint - The industrial hemp sector experienced a significant surge on December 12, driven by news that former President Trump is considering reclassifying marijuana's danger level, which could lower its regulatory status [1] Market Performance - Fu'an Pharmaceutical rose over 15% - Rhine Biology hit the daily limit up - Morning Light Bio increased nearly 7% - Kang En Bei and Fu Ri Electronics both rose around 6% [1] U.S. Market Reaction - U.S. cannabis stocks saw strong performance on Monday: - Canopy Growth surged over 26% - Tilray Brands jumped over 40% - Cronos Group increased by more than 14%, reaching a 52-week high [1] Industrial Hemp Overview - Industrial hemp is characterized by a tetrahydrocannabinol (THC) content of less than 0.3% and does not exhibit psychoactive effects - Its seeds, flowers, leaves, stalks, and roots can be utilized in textiles, food, daily chemicals, and pharmaceuticals [1] Market Growth Forecast - According to Mordor Intelligence, the global industrial hemp market is projected to grow from $2.21 billion in 2023 to $4.97 billion by 2028 - This represents a compound annual growth rate (CAGR) of 17.56% over the next five years [1]